Gil Leibowitz

Predictors of diabetic ketoacidosis in patients with insulin‐deficient diabetes phenotype initiating <scp>SGLT2</scp> inhibitors

Neurodegeneration onset with glucagon-like peptide-1 receptor agonists in people with type 2 diabetes: a real-world multinational cohort study

Beta cells intrinsically sense and limit their secretory activity via mTORC1-RhoA signaling

Mortality, kidney, and safety outcomes with SGLT2 inhibitors versus DPP4 inhibitors in patients with type 2 diabetes treated with systemic glucocorticoids: a real-world exploratory study

Kidney Outcomes With Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Glucose‐Lowering Agents in People With Type 2 Diabetes: A Systematic Review and Meta‐Analysis of Real‐World Data

Normoalbuminuria—is it normal? The association of urinary albumin within the ‘normoalbuminuric’ range with adverse cardiovascular and mortality outcomes: A systematic review and meta‐analysis

Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition

Alpelisib in Intractable Non–Islet-Cell Tumor Hypoglycemia

The effect of steroid injection into the shoulder on glycemia in patients with type 2 diabetes

Pathogenesis of diabesity‐induced kidney disease: role of kidney nutrient sensing

Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes

Proximal Tubule mTORC1 Is a Central Player in the Pathophysiology of Diabetic Nephropathy and Its Correction by SGLT2 Inhibitors

Paving the way to precision medicine for diabetic kidney disease: the PRIORITY trial

VERIFY the role of initial combination therapy in patients with type 2 diabetes

Inhibition of mTORC1 by ER stress impairs neonatal β-cell expansion and predisposes to diabetes in the Akita mouse

Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial

Pancreatic β-Cells Express the Fetal Islet Hormone Gastrin in Rodent and Human Diabetes

GLP-1-RA Corrects Mitochondrial Labile Iron Accumulation and Improves β-Cell Function in Type 2 Wolfram Syndrome

Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial